Cable Hill Partners LLC Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)

Cable Hill Partners LLC cut its holdings in Johnson & Johnson (NYSE:JNJ) by 2.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 7,924 shares of the company’s stock after selling 199 shares during the quarter. Cable Hill Partners LLC’s holdings in Johnson & Johnson were worth $1,146,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in JNJ. IFS Advisors LLC increased its position in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after buying an additional 100 shares in the last quarter. Highline Wealth Partners LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth approximately $31,000. Bay Harbor Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $32,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth approximately $35,000. Finally, Activest Wealth Management acquired a new stake in shares of Johnson & Johnson in the third quarter worth approximately $40,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $165.23 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The business’s fifty day simple moving average is $150.90 and its 200-day simple moving average is $156.06. The firm has a market cap of $397.81 billion, a PE ratio of 24.85, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the prior year, the company posted $2.29 EPS. The company’s quarterly revenue was up 5.3% on a year-over-year basis. Equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.00%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Analyst Ratings Changes

A number of analysts have recently issued reports on JNJ shares. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Morgan Stanley lowered their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Bank of America lowered their price target on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, January 23rd. Citigroup lowered their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Finally, Wells Fargo & Company lowered their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $170.67.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.